AbbVie annual net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Net Income Growth & History (ABBV)
AbbVie's net income was $4.23B for fiscal 2025.
View full AbbVie company overviewAbbVie annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.23B | −$52.0M | −1.22% |
| 2024 | 2024-12-31 | $4.28B | −$585.0M | −12.03% |
| 2023 | 2023-12-31 | $4.86B | −$6.97B | −58.91% |
| 2022 | 2022-12-31 | $11.84B | $294.0M | +2.55% |
| 2021 | 2021-12-31 | $11.54B | $6.93B | +150.04% |
| 2020 | 2020-12-31 | $4.62B | −$3.27B | −41.44% |
| 2019 | 2019-12-31 | $7.88B | $2.19B | +38.60% |
| 2018 | 2018-12-31 | $5.69B | $378.0M | +7.12% |
| 2017 | 2017-12-31 | $5.31B | −$644.0M | −10.82% |
| 2016 | 2016-12-31 | $5.95B | $809.0M | +15.73% |
| 2015 | 2015-12-31 | $5.14B | $3.37B | +189.97% |
| 2014 | 2014-12-31 | $1.77B | — | — |
AbbVie quarterly net income
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.61B | $2.67B | +285.18% |
| Q1 2026 | 2026-03-31 | $695.0M | −$591.0M | −45.96% |
| Q4 2025 | 2025-12-31 | $1.82B | $1.84B | — |
| Q3 2025 | 2025-09-30 | $186.0M | −$1.38B | −88.08% |
| Q2 2025 | 2025-06-30 | $938.0M | −$432.0M | −31.53% |
| Q1 2025 | 2025-03-31 | $1.29B | −$83.0M | −6.06% |
| Q4 2024 | 2024-12-31 | −$22.0M | −$844.0M | — |
| Q3 2024 | 2024-09-30 | $1.56B | −$217.0M | −12.20% |
| Q2 2024 | 2024-06-30 | $1.37B | −$654.0M | −32.31% |
| Q1 2024 | 2024-03-31 | $1.37B | $1.13B | +472.80% |
| Q4 2023 | 2023-12-31 | $822.0M | −$1.65B | −66.76% |
| Q3 2023 | 2023-09-30 | $1.78B | −$2.17B | −54.98% |
| Q2 2023 | 2023-06-30 | $2.02B | $1.10B | +119.05% |
| Q1 2023 | 2023-03-31 | $239.0M | −$4.25B | −94.68% |
| Q4 2022 | 2022-12-31 | $2.47B | −$1.57B | −38.85% |
| Q3 2022 | 2022-09-30 | $3.95B | $770.0M | +24.22% |
| Q2 2022 | 2022-06-30 | $924.0M | $158.0M | +20.63% |
| Q1 2022 | 2022-03-31 | $4.49B | $937.0M | +26.37% |
| Q4 2021 | 2021-12-31 | $4.04B | $4.01B | +11133.33% |
| Q3 2021 | 2021-09-30 | $3.18B | $871.0M | +37.74% |
| Q2 2021 | 2021-06-30 | $766.0M | $1.50B | — |
| Q1 2021 | 2021-03-31 | $3.55B | $543.0M | +18.04% |
| Q4 2020 | 2020-12-31 | $36.0M | −$2.77B | −98.71% |
| Q3 2020 | 2020-09-30 | $2.31B | $424.0M | +22.51% |
| Q2 2020 | 2020-06-30 | −$738.0M | −$1.48B | — |
| Q1 2020 | 2020-03-31 | $3.01B | $554.0M | +22.56% |
| Q4 2019 | 2019-12-31 | $2.80B | $4.63B | — |
| Q3 2019 | 2019-09-30 | $1.88B | −$863.0M | −31.42% |
| Q2 2019 | 2019-06-30 | $741.0M | −$1.24B | −62.63% |
| Q1 2019 | 2019-03-31 | $2.46B | −$327.0M | −11.75% |
| Q4 2018 | 2018-12-31 | −$1.83B | −$1.88B | — |
| Q3 2018 | 2018-09-30 | $2.75B | $1.12B | +68.42% |
| Q2 2018 | 2018-06-30 | $1.98B | $68.0M | +3.55% |
| Q1 2018 | 2018-03-31 | $2.78B | $1.07B | +62.65% |
| Q4 2017 | 2017-12-31 | $52.0M | −$1.34B | −96.26% |
| Q3 2017 | 2017-09-30 | $1.63B | $33.0M | +2.07% |
| Q2 2017 | 2017-06-30 | $1.92B | $305.0M | +18.94% |
| Q1 2017 | 2017-03-31 | $1.71B | $357.0M | +26.37% |
| Q4 2016 | 2016-12-31 | $1.39B | −$126.0M | −8.31% |
| Q3 2016 | 2016-09-30 | $1.60B | $359.0M | +28.97% |
| Q2 2016 | 2016-06-30 | $1.61B | $244.0M | +17.86% |
| Q1 2016 | 2016-03-31 | $1.35B | $332.0M | +32.49% |
| Q4 2015 | 2015-12-31 | $1.52B | — | — |
| Q3 2015 | 2015-09-30 | $1.24B | — | — |
| Q2 2015 | 2015-06-30 | $1.37B | — | — |
| Q1 2015 | 2015-03-31 | $1.02B | — | — |
AbbVie net income trends
Over the last five fiscal years, AbbVie's net income decreased from $4.62B to $4.23B, a change of −$390.0M. The latest reported quarter, Q2 2026, shows $3.61B.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
FDA clears at-home Skyrizi induction for Crohn’s disease
AbbVie ($ABBV) received FDA approval for subcutaneous induction dosing of Skyrizi in adults with moderately to severely active Crohn’s disease. Patients can now begin treatment at home using an on-body injector, extending that delivery opti ...
AbbVie meets pivotal hidradenitis endpoint with lutikizumab
AbbVie ($ABBV) reported that lutikizumab met the main endpoint and all eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At week 16, 31.4% of treated patients achieved HiSCR75, c ...
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
